Form 4: Arcadia Biosciences CFO Mark Kawakami Reports Stock Option Grant

Arcadia Biosciences' Chief Financial Officer, Mark Kawakami, reported the acquisition of stock options in the company.

Summary

• On August 19, 2024, Mark Kawakami, the Chief Financial Officer of Arcadia Biosciences, Inc., was granted stock options to purchase 20,000 shares of common stock at an exercise price of $2.71 per share.
• The options vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments.
• Following the reported transaction, Kawakami directly owns 21,487 derivative securities.
• The options expire on August 19, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

This is a standard practice for publicly traded companies to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies, particularly in growth-oriented sectors like biotechnology and agriculture.
• The vesting schedule of 25% after one year and the remainder monthly over three years is a typical vesting arrangement.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CFO's performance leads to company growth.
• The grant incentivizes the CFO, potentially benefiting employees through improved company performance.

Key Dates

Keywords

stock options, Form 4, Arcadia Biosciences, RKDA, CFO, Mark Kawakami, insider trading, beneficial ownership